Hospital de la Cite-de-la-Sante

Laval, Quebec H7M 3L9

0 studies enrolling now · 1 studies all time

What they study most

HER2 Positive Breast Cancers

Studies at this site

• A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer — Completed